Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
18.36
-0.12 (-0.65%)
At close: Dec 15, 2025, 4:00 PM EST
18.36
0.00 (0.00%)
After-hours: Dec 15, 2025, 4:04 PM EST
Bicara Therapeutics Employees
Bicara Therapeutics had 55 employees as of December 31, 2024.
Employees
55
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,209,473
Market Cap
1.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCAX News
- 9 days ago - Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 - GlobeNewsWire
- 14 days ago - Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - GlobeNewsWire
- 20 days ago - Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout - Seeking Alpha
- 5 weeks ago - Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - GlobeNewsWire
- 3 months ago - Bicara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus - Seeking Alpha